Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Xoma Corp (XOMA)

Xoma Corp (XOMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Xoma Corp 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 USA

www.xoma.com P: 510-204-7200

Description:

XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1' with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California.

Key Statistics

Overview:

Market Capitalization, $K 286,105
Enterprise Value, $K 256,765
Shares Outstanding, K 11,635
Annual Sales, $ 4,760 K
Annual Net Income, $ -40,830 K
Last Quarter Sales, $ 1,830 K
Last Quarter Net Income, $ -20,110 K
EBIT, $ -40,950 K
EBITDA, $ -40,050 K
60-Month Beta 0.58
% of Insider Shareholders 7.20%
% of Institutional Shareholders 95.92%
Float, K 10,797
% Float 92.80%
Short Volume Ratio 0.20

Growth:

1-Year Return 36.49%
3-Year Return -34.06%
5-Year Return 102.72%
5-Year Revenue Growth -10.19%
5-Year Earnings Growth -67.30%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.49 on 03/08/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm -2.66
EPS Growth vs. Prev Qtr 18.33%
EPS Growth vs. Prev Year 23.44%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 10/18/16

XOMA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -25.17%
Return-on-Assets % -17.08%
Profit Margin % -857.77%
Debt/Equity 1.40
Price/Sales 59.30
Price/Cash Flow N/A
Price/Book 3.16
Book Value/Share 7.72
Interest Coverage -70.63
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar